Syrrhoea is a common metabolic disease, and its incidence is closely related to the rise in the level of in vase. Long-term hyperureaemia causes urea acid crystals to accumulate in joints and surrounding tissues, causing symptoms such as joint pain, red edema, and seriously affecting the quality of life of patients. While traditional urinate-reducing drugs such as beryllol, phenylbromomalon and others can reduce urea acid to some extent, there are limitations, such as the potential for severe skin allergies and the risk of liver damage to phenylbrom. As a result, the development of a new type of urea acid-selective URAT1 inhibitor has become a hot spot in medicine.
URAT1 is the key trans-shipment protein in the kidneys responsible for urea-heavy absorption. Selective URAT1 inhibitors reduce the renal respiration of urea by inhibiting the activity of URAT1 in a specific way, thus facilitating the excretion of urea from the urine for the purpose of reducing blood urea levels.
At present, there are a number of selective URAT1 inhibitors at different stages of research or used in clinical applications. For example, Recinad, a selective URAT1 inhibitor that was studied earlier, has demonstrated a significant urea acid reduction effect in several clinical trials. Recinard is more effective in reducing blood urea levels than traditional drugs and has relatively few adverse effects, mainly in the form of mild gastrointestinal discomfort. However, it also found problems in clinical applications, such as long-term use that may increase the risk of kidney stones, which also limits its widespread use.
In recent years, a new generation of selective URAT1 inhibitors has emerged. Of these, non-Bussotán received considerable attention. The non-Bussotan is highly selective for URAT1 and has a strong and persistent effect on the reduction of urine acid. In clinical trials, non-Bussotan not only reduces blood urea levels rapidly, reaching the standard of blood urea for most patients, but is also safe and has a low incidence of drug-related adverse effects, especially those of severe adverse effects, which are significantly lower than those of traditional drugs. It is undoubtedly a new treatment option for those who use traditional drugs that are ineffective or unable to withstand the adverse effects of traditional medicines.
In addition to the above-mentioned drugs, a number of selective URAT1 inhibitors in the early stages of development also show good prospects. Through an in-depth study of the structure and functions of URAT1, researchers continuously optimize the molecular structure of inhibitors in order to improve their inhibitive activity, selectivity and safety. These new drugs have demonstrated excellent urine reduction effects in animal experiments and have a small effect on liver and kidney function, which is expected to lead to more breakthroughs in the future in the treatment of gout.
Selective URAT1 inhibitor as a new form of urea acid abatement has brought a new dawn for the treatment of pain. They have improved and improved their effectiveness and safety over traditional medicines. But we should also see that there are still some deficiencies in these drugs, such as insufficient data on the long-term safety of some drugs and relatively high prices. With further medical research and technological advances, it is believed that selective URAT1 inhibitors will continue to improve, providing more effective, safer and economical treatment for the large number of patients with ailments, helping them to alleviate their suffering, improve their quality of life and enable them to return to normal life.
